// App-Quantinova.ai

342 : Effects of Tamoxifen on the Mutant Allele Burden and Disease Course in Patients with Myeloproliferative Neoplasms – Results of the Tamarin Study

Researchers

Presenter

  • Claire Harrison

Principal Investigators

  • Rebecca H. Boucher

  • Thomas McKerrell

  • Aimee Jackson

  • Rachel S Fletcher

  • Adam J. Mead

  • Steve Knapper

  • Joanne Ewing

  • Nauman M Butt

  • Manish Jain

  • Sebastian Francis

  • Fiona J Clark

  • Jason Coppell

  • Mary Frances McMullin

  • Frances Wadelin

  • Srinivasan Narayanan

  • Dragana Milojkovic

  • Mark W. Drummond

  • Mallika Sekhar

  • Maike Paramor

  • James Roberts

  • Rachel Glover

  • Erica Harris

  • Luigi Grassi

  • Alba Rodriguez-Meira

  • Jason Carroll

  • Jos-Ezequiel Martn

  • Giuditta Corbizi Fattori

  • Zijian Fang

  • Anna L Godfrey

  • Simn Mndez-Ferrer

Medical Centers

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • University of Cambridge, Department of Oncology, Cambridge, United Kingdom

  • Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

  • Department of Oncology, University of Cambridge, Cambridge, United Kingdom

  • Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom

  • Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • Institute of Cancer & Genetics, Cardiff University, Cardiff, Wales, United Kingdom

  • University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom

  • Department of Diabetes and Endocrinology, St James University Hospital, Leeds, United Kingdom

  • Haematology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom

  • Queen Elizabeth Hospital - Histopathology - University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom

  • Royal Devon and Exeter Hospital, Exeter, United Kingdom

  • Centre for Medical Education,Queen's University,Belfast,United Kingdom

  • Nottingham City Hospital, Nottingham, United Kingdom

  • Haematology, University Hospital Southampton, Southampton, United Kingdom

  • Imperial College, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Kings College London, London, United Kingdom

  • University of Cambridge, Cambridge, United Kingdom

  • IGF Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

  • MRC Centre for Computational Biology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

Disease

  • Myeloid neoplasms

  • Breast cancer

  • Venous thrombosis

  • Solid malignancies

  • Retinal vasculopathy with cerebral leukodystrophy

Biomarkers

  • Calreticulin

  • Cluster of Differentiation 34

Drug/Treatment

  • Interferon

  • Tamoxifen

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved